<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522301</url>
  </required_header>
  <id_info>
    <org_study_id>07-080</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-07080</secondary_id>
    <secondary_id>BAYER-MSKCC-07-080</secondary_id>
    <nct_id>NCT00522301</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission</brief_title>
  <official_title>A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with
      ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in at least the second
      remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the 12-month progression-free survival (PFS) rate of women with ovarian
           epithelial, fallopian tube, or peritoneal cancer in second or greater remission treated
           with oral sorafenib tosylate.

      Secondary

        -  To determine the safety and tolerability of prolonged treatment with oral sorafenib
           tosylate in women with a history of recurrent ovarian cancer.

        -  To correlate serum markers of angiogenesis (i.e., VEGF and bFGF) and tumor markers pAKT,
           HIF-1 α , and VEGF with 12-month PFS.

      OUTLINE: Patients receive oral sorafenib twice a day on days 1-28. Treatment repeats every 28
      days for up to 24 months in the absence of disease progression or unacceptable toxicity.

      Patients undergo tumor tissue and blood sample collection at baseline, every 12 weeks during
      study, and after completion of study therapy for pharmacokinetic studies. Samples are
      analyzed for soluble markers of angiogenesis (i.e., VEGF and bFGF) via ELISA and HIF-1 α,
      VEGF, and pAKT via IHC staining.

      After completion of study treatment, patients are followed at 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Rate at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>All 5 patients experienced a rash. As a result, all 5 were either advised to withdraw from the protocol, or withdrew themselves from the protocol. The outcome was not met.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Oral Sorafenib (BAY43-9006)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed epithelial carcinoma arising in the ovary, fallopian tube, or
             peritoneum

               -  Any stage and grade at diagnosis

          -  Must have received initial cytoreductive surgery and chemotherapy with ≥ 1
             platinum-based chemotherapy regimen

               -  Persistent or recurrent disease after initial therapy

          -  In complete clinical remission after chemotherapy for recurrent disease, meeting all
             of the following criteria:

               -  CA125 ≤ 35 units/L

               -  Normal physical examination

               -  No definite evidence of disease by CT scan of the abdomen and pelvis

                    -  Lymph nodes and/or soft tissue abnormalities ≤ 1.0 cm are not considered
                       definite evidence of disease

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status 70-100%

          -  Life expectancy &gt; 3 months

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  INR &lt; 1.5 OR PT/PTT within normal limits

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  Urinalysis negative for protein

               -  If urinalysis shows 1+ protein by dipstick or protein ≥ 30-100 mg/dL by
                  semi-quantitative assay, a 24-hour urine collection is required

                    -  Eligible patients must have a total urinary protein ≤ 500 mg AND measured
                       creatinine clearance ≥ 50 mL/min from a 24-hour urine collection

          -  Bilirubin ≤ 1.5 times ULN

          -  AST and ALT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Stable blood pressure (BP) measurement required on 3 separate days prior to the start
             of treatment

          -  No peripheral neuropathy &gt; grade 1

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Other invasive malignancies within the past 5 years, except nonmelanoma skin cancer

          -  Uncontrolled concurrent illness or medical condition including, but not limited to,
             any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Uncontrolled diabetes

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Uncontrolled hypertension defined as a persistent BP &gt; 150/100 mm Hg (or a persistent
             BP &gt; 180/90 mm Hg if the patient has a history of isolated systolic hypertension)
             despite ≥ 2 attempts at antihypertensive medication dosage adjustment ≥ 2 weeks apart

          -  Thrombolic or embolic events such as cerebrovascular accident, including transient
             ischemic attack, within the past 6 months

          -  Pulmonary hemorrhage or bleeding event ≥ grade 2 within 4 weeks of the first dose of
             study drug

          -  Other hemorrhage or bleeding event ≥ grade 3 within 4 weeks of the first dose of study
             drug

          -  Serious nonhealing wound, ulcer, or bone fracture

          -  Evidence or history of bleeding diathesis or coagulopathy

          -  Inability to take oral medications or gastrointestinal condition that compromises
             absorption

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sorafenib tosylate

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

          -  No prior sorafenib tosylate or other inhibitors of MAPK signaling intermediates or
             angiogenesis inhibitors

          -  No prior cancer treatment that would contraindicate protocol therapy

          -  More than 4 weeks since prior radiotherapy

          -  More than 3 weeks since prior chemotherapy, biological therapy, or immunotherapy

          -  More than 1 week since prior hormonal therapy for cancer treatment

        Exclusion criteria:

          -  Major surgery (i.e., laparotomy) within the past 4 weeks or minor surgery within the
             past 2 weeks

               -  Placement of a vascular access device is not considered minor surgery

          -  Concurrent combination antiretroviral therapy for HIV-positive patients

          -  Concurrent St. John wort, rifampin, or enzyme-inducing anticonvulsants (e.g.,
             carbamazepine, phenytoin, or phenobarbital)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William P. Tew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2007</study_first_submitted>
  <study_first_submitted_qc>August 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2007</study_first_posted>
  <results_first_submitted>October 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Sorafenib (BAY43-9006)</title>
          <description>Sorafenib will be administered as 400 mg orally daily x 28 days (continuous).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Sorafenib (BAY43-9006)</title>
          <description>Sorafenib will be administered as 400 mg orally daily x 28 days (continuous).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Rate at 12 Months</title>
        <description>All 5 patients experienced a rash. As a result, all 5 were either advised to withdraw from the protocol, or withdrew themselves from the protocol. The outcome was not met.</description>
        <time_frame>1 year</time_frame>
        <population>Protocol terminated prior to primary outcome evaluation. All 5 patient were evaluable for toxicity only.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Sorafenib (BAY43-9006)</title>
            <description>Sorafenib will be administered as 400 mg orally daily x 28 days (continuous).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Rate at 12 Months</title>
          <description>All 5 patients experienced a rash. As a result, all 5 were either advised to withdraw from the protocol, or withdrew themselves from the protocol. The outcome was not met.</description>
          <population>Protocol terminated prior to primary outcome evaluation. All 5 patient were evaluable for toxicity only.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Sorafenib (BAY43-9006)</title>
          <description>Sorafenib will be administered as 400 mg orally daily x 28 days (continuous).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination as it would not meet it's primary endpoint of improved survival. None of the patients completed the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William Tew</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4220</phone>
      <email>teww@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

